polycystic ovarian syndrome (pcos )
DESCRIPTION
Polycystic ovarian syndrome (PCOS ). Wei Zhang OB/GYN Hospital, Fudan University. Content. OVERVIEW of PCOS PATHOPHYSIOLOGY SIGNS and SYMPTOMS DIAGNOSTIC CRITERIA TREATMENT. OVERVIEW. PCOS. 1 st described by Stein and Leventhal as a triad of amenorrhea, obesity and hirsutism (1935) - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/1.jpg)
Polycystic ovarian syndrome(PCOS)
Polycystic ovarian syndrome(PCOS)
Wei Zhang
OB/GYN Hospital, Fudan University
![Page 2: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/2.jpg)
Content
OVERVIEW of PCOS
PATHOPHYSIOLOGY
SIGNS and SYMPTOMS
DIAGNOSTIC CRITERIA
TREATMENT
![Page 3: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/3.jpg)
OVERVIEWOVERVIEW
![Page 4: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/4.jpg)
PCOS
1 st described by Stein and Leventhal as a triad of amenorrhea, obesity and hirsutism (1935)
The symptoms and severity of the syndrome vary greatly among affected women
It is one of the leading causes of female infertility
![Page 5: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/5.jpg)
Definition & Abbreviations
Definition :Polycystic ovarian syndrome is a common endocrine disfunction typified by oligo-ovulation or anovulation, signs of androgen excess, and multiple small ovarian cysts
Abbreviations PCOS = Polycystic Ovarian Syndrome PCO= Polycystic Ovarian
![Page 6: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/6.jpg)
Incidence
PCOS is the most common disorder of reproductive-aged women
Affects approximately 4-12%
PCOS appears to equally affect all races and nationalities
![Page 7: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/7.jpg)
Etiology
Genetic basis Aggregation of the syndrome within
families • An increased prevalence has been noted
between affected individuals and their sisters and mothers
• The first-degree male relatives of women with PCOS have significantly higher circulating DHEAS levels
.
![Page 8: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/8.jpg)
Environment causes Life style Exercise Diet Androgen exposure, et. al
![Page 9: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/9.jpg)
Interaction of Genetics and environment
PCOS may be a genetically determined
ovarian disorder , the heterogeneity can be explained on the basis of interaction of the disorder with other genes and with the environment
![Page 10: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/10.jpg)
PATHOPHYSIOLOGYPATHOPHYSIOLOGY
![Page 11: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/11.jpg)
Hypothalamus
GnRH
Pituitary
FSH LH
ProgesteroneEstradiol
Ovary
内膜
Reproductive cycle regulated by HPO axis
Gn
![Page 12: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/12.jpg)
![Page 13: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/13.jpg)
Pathopysiologyz:What we think we know
Abnormal gonadotropin secretion Excess LH and low, tonic FSH
Hypersecretion of androgens Disrupts follicle maturation Substrate for peripheral aromatization
Negative feedback on pituitary Decreased FSH secreation
Insulin resistance, Elevated insulin levels
![Page 14: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/14.jpg)
Disorder of H-P-O axis
Increased GnRH from hypothalamus Excessive LH secretion relative to FSH by
pituitary gland LH stimulates ovarian thecal cells to
produce excessive androgen Ineffective suppression of the LH pulse
frequency by estradiol and progesterone Androgen excess increases LH by blocking
the hypothalamic inhibitory feedback of progesterone
![Page 15: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/15.jpg)
LH, FSH androgenEstrogen
GnRH
Anovulation
H-P-O axis Dysfunction in PCOS
![Page 16: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/16.jpg)
Abnormal steroidogenesis
Intraovarian androgen excess results in excessive growth of small ovarian follicles
Follicular maturation is inhibited
Excess androgen causes thecal and stromal hyperplasia
![Page 17: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/17.jpg)
PCO
These "cysts" are actually immature follicles. The follicles development stopped at an early antral stage due to the disturbed ovarian function
Polycystic is >12 follicles per ovary less than 10mm in diameter, ovary itself is enlarged
![Page 18: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/18.jpg)
Metabolism disorder
Hyperinsulinemia Excess insulin production and insulin
resistance Hyperinsulinemia contributes to
hyperandrogenism through production in the theca cell and through its suppressive effects on sex hormone binding globulin production by the liver
Hyperandrogenism vs. hyperinsulinemia: Which came first?
Dyslipidemia
![Page 19: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/19.jpg)
Current theories of pathopysiology
AutosomalDominant Gene
Insulin Resistance
PCOS
GnRH
LH
A
E2DownstreamSignal Defect
A=androgens, E2=estradiol
![Page 20: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/20.jpg)
SIGNS and SYMPTOMSIGNS and SYMPTOM
![Page 21: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/21.jpg)
Clinical Features of PCOS
Hyperandrogenism Hirsutism Acne
Chronic anovulation (irregular menses)
Irregular menses
Infertility
Endocrine Dysfunction Obesity Insulin resistance
• Acanthosis Nigricans• Impaired Glucose Tolerance and Type 2 Diabetes Mellitus
Dyslipidemia Metabolic Syndrome and Cardiovascular Disease
Polycystic ovaries
![Page 22: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/22.jpg)
Hyperandrogenism
Hirsutism, acne, male pattern balding, alopecia
50-90% patients have elevated serum androgen levels
Rare: increased muscle mass, deepening voice,
![Page 23: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/23.jpg)
Hirsutism:Ferriman-Gallwey Scoring System
Acne: 50%Mild moderate severe
![Page 24: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/24.jpg)
Facial Hirsutism in PCOS
![Page 25: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/25.jpg)
Menstrual Dysfunction
Oligomenorrhea : 70-75 %Amenorrhea: 20 %Regular cycles: 5-10 %
Infertility: 30-70%
Chronic anovulation/oligo-ovulation
![Page 26: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/26.jpg)
Menstrual Dysfunction
Oligo or amenorrhea Menstrual irregularity typically begins in the
peripubertal period
Reduction in ovulatory events leads to deficient progesterone secretion
Chronic estrogen stimulation of the endometrium with no progesterone for differentiation—intermittent breakthrough bleeding or dysfunctional uterine bleeding
Increased risk for endometrial hyperplasia and/or endometrial CA
![Page 27: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/27.jpg)
INFERTILITY
Intermittent ovulation or anovulation
Inherent ovarian disorder—studies show reduced rated of conception despite therapy with clomid
![Page 28: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/28.jpg)
Obesity
Prevalence of obesity varies from 30-75%
2/3 of patients with PCOS who are not obese have excessive body fat and central adiposity
Obese patients can be hirsute and/or have menstrual irregularities without having PCOS
![Page 29: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/29.jpg)
Insulin Resistance
> 80% are hyperinsulinemic and have insulin resistance (independent of obesity)
![Page 30: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/30.jpg)
Acanthosis Nigricans
• Velvety plaques on nape of neck and intertriginous areas
• Epidermal hyperkeratosis
• Associated with insulin resistance
![Page 31: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/31.jpg)
Ovarian Abnormalities
Thickened sclerotic cortex
Multiple follicles in peripheral location
80% of women with PCOS have classic cysts
![Page 32: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/32.jpg)
![Page 33: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/33.jpg)
Associated Medical Conditions
Increased risk of developing Type 2 Diabetes and Gestational diabetes
Low HDL and high triglyceridesSleep apneaNonalcoholic steatohepatitisMetabolic syndrome—43% of PCOS
patients (2 fold higher than age-matched population)
Elevated heart diseaseAdvanced atherosclerosis
![Page 34: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/34.jpg)
Consequences of PCOS
Short-term consequences Irregular menses Hirsutism/acne/androgenic alopecia Infertility Obesity Metabolic disturbances : Abnormal lipid
levels/glucose intolerance
Long-term consequences Diabetes mellitus (DM) Cardiovascular disease(CVD) Endometrial cancer
![Page 35: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/35.jpg)
Consequences of PCOS
PCOS
hyperandrogen
Elevated insulin
diabetes
Menstrual irregularity
Obesity
Hirsutism, acne
CVD
Dyslipidemia
infertility
Sh
ort-term
co
nseq
uen
cesL
on
g-term
co
nseq
uen
ces
hyperplasia/cancer
![Page 36: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/36.jpg)
DIAGNOSTIC CRITERIADIAGNOSTIC CRITERIA
![Page 37: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/37.jpg)
Difficult to diagnosis Changing criteria Varying symptoms over time
• Not all women with PCOS have polycystic ovaries (PCO), nor do all women with ovarian cysts have PCOS
• although a pelvic ultrasound is a major diagnostic tool, it is not the only one
• The diagnosis is straightforward using the Rotterdam criteria
![Page 38: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/38.jpg)
NIH Criteria(1990) Menstrual irregularity due to anovulation or
oligo-ovulation Evidence of clinical or biochemical
hyperandrogenism• Hirsutism, acne, male pattern baldness• High serum androgen levels
Exclusion of other causes (CAH, tumors, hyperprolactinemia)
![Page 39: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/39.jpg)
Menstrual irregularity due to anovulation oligo-ovulation
Evidence of clinical or biochemical hyperandrogenism
Polycystic ovaries by US• 12 or more follicles measuring 2-9 mm in diameter• Increased ovarian volume (>10 cm 3 )
Exclusion of other causes (CAH, tumors, hyperprolactinemia)
In 2003 in Rotterdam, Netherlands, a consensus meeting between the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine (ESHRE/ASRM) redefined PCOS
2003 Rotterdam Criteria (2 out of 3)
![Page 40: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/40.jpg)
Differential Diagnosis
1. Hyperprolactinemia Prominent menstrual dysfunction Little hyperandrogenism
2. Congenital Adrenal Hyperplasia morning serum 17-hydroxyprogesterone
concentration greater than 200 ng/dL in the early follicular phase strongly suggests the diagnosis
confirmed by a high dose (250 mcg) ACTH stimulation test: post-ACTH serum 17-hydroxyprogesterone value less than 1000 ng/dL
![Page 41: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/41.jpg)
3. Ovarian and adrenal tumors serum testosterone concentrations are always
higher than 150 ng/dL adrenal tumors: serum DHEA-S
concentrations higher than 800 mcg/dL LOW serum LH concentrations
4. Cushing’s syndrome5. Drugs: danazol; OCPs with high
androgenicity
![Page 42: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/42.jpg)
Diagnostic Approaches
• Clinical history (hair growth rate, onset of symptoms)
• Physical examination (hirsutism or virilization, rounded facies, buffalo hump)
• Laboratory testing (hormones)
• Ultrasonography (ovary, endometrium)
![Page 43: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/43.jpg)
Laboratory Testing
Fasting glucose: elevated 2 hour OGTT: elevated Fasting insulin: elevated Free testosterone: elevatedDHEA-S: normal17-hydroxyprogesterone: normalPelvic USLipids profile
![Page 44: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/44.jpg)
Total Testosterone (T)DHEA-S (DS)17-hyroxyprogesterone (17-OHP)
T > 200 ng/dlDS > 700 μg/dl
Suspect Tumor
17-OHP > 2 ng/ml
Suspect CAH
T Elevated ±DS Elevated
DS Elevated
T & DS Normal PCOS
Adrenal
Idiopathic
Laboratory Evaluation
![Page 45: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/45.jpg)
TREATMENTTREATMENT
![Page 46: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/46.jpg)
Treatment
Goals of PCOS Treatment Restoration a normal cycle and fertility Lowering of insulin levels Treatment of hirsutism, acne Prenvention of endometrial cancer Prevention of DM,CVD and metabolic
syndrome
![Page 47: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/47.jpg)
Treatment Option
Lifestyle modification
Anti-androgens
Insulin lowering agents
Induced ovulation-for pregnancy desired
![Page 48: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/48.jpg)
Lifestyle modification
Weight loss:
Low-carbohydrate diets
sustained regular exercise
90% of anovulatory women restored to full
ovulation despite relatively small amounts
of weight loss following exercise and
change of diet
BMI of 21 is ideal but the patient often
respond to much less stringent body mass
index
![Page 49: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/49.jpg)
Anti-Androgen
OCPs: first option when fertility is not desired Decrease in LH secretion and decrease in
androgen production Increase in hepatic production of sex-hormone
binding globulin(SHBG) Decreased bioavailablity of testosterone Decreased adrenal androgen secretion Regular withdrawal bleeding Prevention of endometrial hyperplasia
![Page 50: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/50.jpg)
Spironolactone, 50-200 mg per day Androgen receptor blockade
Steroid enzyme inhibition
Aldosterone antagonism Lower blood pressure Potassium sparing
![Page 51: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/51.jpg)
ProgestinsProgestins
progesterone withdrawal: every 1 to 3 months Regular withdrawal bleeding Prevention of endometrial hyperplasia and cancer
regimens include MPA: 5 to 10 mg daily for 10-14 days Micronized progesterone: 200 mg each evening
for 10-14 days
![Page 52: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/52.jpg)
Insulin-Sensitizing Agents
Induction of ovulation
Some reduced hair growth
Improved glucose utilization
Lowered serum insulin
Lipid lowering properties
![Page 53: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/53.jpg)
Metformin Dosage: 1500-2550 mg per day Clinically significant responses not regularly
observed at doses less than 1000 mg per day Treat with cyclic progestin to reduce
endometrial hyperplasia if regular menses not attained
•10 mg for 7 to 10 days every one to three months
![Page 54: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/54.jpg)
Infertility
Weight loss—reduction in serum testosterone concentration and resumption of ovulation
Clomid: 80% will ovulate, 50% will conceive
Metformin will restore ovulation and menses in > 50% of
patients added to clomid, improves ovulatory rates
CC/FSH/hCG Laparoscopic surgery: wedge resections,
laparoscopic ovarian laser electrocautery IVF
![Page 55: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/55.jpg)
Pathophysiology
Clinincal Features of PCOS
Diagnosis criteria
Treatment Option of PCOS
Key points
![Page 56: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/56.jpg)
References John O. Schorge . Williams Gynecology,2008
ISBN 978-0-07-147257-9
丰有吉 . 妇产科学,八年制本科教材,人民卫生出版社, 2008
曹泽毅 .中华妇产科学 . 人民卫生出版社 .2005
![Page 57: Polycystic ovarian syndrome (PCOS )](https://reader035.vdocument.in/reader035/viewer/2022062309/56813f63550346895daa3568/html5/thumbnails/57.jpg)
The ENDThe END
2012.06.15